

SCIENTIFIC ADVISORY BOARD

PROFESSOR PATRICK AEBISCHER

Professor Aebischer is an MD by training and is presently Professor of Neurosciences and President at the Swiss Federal Institute of Technology in Lausanne, Switzerland. He is an internationally recognised leader in the area of gene therapy for neurodegenerative diseases. He has conducted gene therapy clinical trials for various neurological diseases and is currently focusing his interest on the application of lentiviral vectors for neurodegenerative diseases, including Parkinson's disease, Huntington's disease and motor neuron diseases. He advises Oxford BioMedica on the utilisation of EIAV vectors for application within the nervous system.

DR KRYS BANKIEWICZ

Dr Bankiewicz is Professor of Neurological Surgery at the University of California and Scientist at Lawrence Berkeley National Laboratory, USA. Dr Bankiewicz is internationally recognised for his work on gene and cell delivery into the central nervous system. His main area of expertise focuses on *in vivo* models of Parkinson's disease, neuroimaging, the dopaminergic system and convection enhanced delivery of viral vectors in the brain. He advises the Company on preclinical aspects of gene transfer technology.

PROFESSOR BEVERLY L DAVIDSON

Professor Davidson is Roy J Carver Professor of Internal Medicine, Physiology, Biophysics and Neurology, University of Iowa College of Medicine, USA. Professor Davidson is internationally recognised for her work on viral mediated gene transfer to the eye and brain, as well as to peripheral organs including the liver, lung and muscle. Her major research focus is vector development with particular emphasis on therapies for diseases of the central nervous system. She advises Oxford BioMedica on its activities in vector biology and vector host interactions, and applications of recombinant retroviruses for neurodegenerative disease gene therapy.

PROFESSOR ADRIAN L HARRIS

Professor Harris is Professor of Clinical Oncology and Director of the Cancer Research UK Medical Oncology Unit at the Churchill Hospital, Oxford. A leading authority on cancer therapies, including gene therapy, Professor Harris provides strategic clinical direction for the development of gene-based therapeutics for optimal integration with current and new anti-cancer treatment regimes. His research has led to a technique utilising a novel gene-switch mechanism (hypoxia response element) that will selectively activate genes in solid tumours, and which Oxford BioMedica has acquired. He has been the Principal Investigator in the Company's clinical trials of MetXia in breast cancer.

DR J WILLIAM LANGSTON

Dr Langston is the founder, Scientific Director and Chief Operating Officer of the Parkinson's Institute in Sunnyvale, California, USA. He is internationally recognised for the discovery of the link between MPTP and parkinsonism, which has provided an entirely new tool to study neurodegeneration in Parkinson's disease and stimulated great interest in finding environmental factors that may cause the disease. His current research interests include the study of mechanisms of neuronal degeneration, the aetiology of Parkinson's disease, and the development of new strategies to slow or halt disease progression. Dr Langston serves on numerous editorial boards and advisory committees and is Chief Scientific Advisor for the Michael J Fox Foundation for Parkinson's Disease Research.

DR PETER L STERN

Dr Stern is Head of the Cancer Research UK Department of Immunology at the Paterson Institute for Cancer Research. He is an expert in tumour immunology and is involved in numerous international collaborations in research and clinical oncology. He advises the company on tumour targeting technologies including those related to 5T4.

PROFESSOR DAVID J WAXMAN

Professor Waxman is Professor of Cell and Molecular Biology at Boston University and Professor of Medicine at Boston University, School of Medicine, Massachusetts, USA. He is a leading authority on cytochrome P450 enzymes and genes, and on their role in metabolism leading to bioactivation of anti-cancer drugs. He has made major contributions to the development of P450-based prodrug activation strategies for cancer gene therapy, and he is advising Oxford BioMedica on the application of P450-based technologies in the clinic.

